US FDA Gives Sponsors Some Leeway In Studying Drug Effects On Driving
Executive Summary
Final guidance on evaluating drug effects on ability to operate a motor vehicle has been slightly modified in response to suggestions by Eisai, Pfizer and Merck.
You may also be interested in...
Drug Effects On Driving Need Tiered Evaluation, FDA Says; Patient Reports Inadequate
Draft guidance describes various analyses and studies that can determine a drug’s effect on driving but doesn’t offer much advice on how to determine when a drug needs to progress to a higher level of scrutiny.
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.